Summary
Economic appraisal of Pharmaceuticals is becoming increasingly important. In a retrospective study of patient records from 58 organ or bone marrow-transplanted patients with systemic mycoses, the cost-effectiveness of treatment with a liposomal amphotericin B formulation was compared with that of conventional amphotericin B. Treatment with liposomal amphotericin B results in fewer adverse reactions, increased life expectancy and higher costs than treatment with conventional amphotericin B.
Pricing liposomal amphotericin B at about SEK6000 per patient treatment day will result in an additional cost per life-year gained of about SEK150 000 relative to that using conventional amphotericin B for patients receiving kidney, kidney and pancreas, or pancreas transplants. For liver and bone marrow transplant (BMT) recipients the marginal cost-effectiveness ratio was about SEK195 000 and SEK150 000 per life-year gained. Compared with alternative use of resources in society and health care, use of liposomal amphotericin B rather than conventional amphotericin treatment can be considered cost-effective at the price assumed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bismuth H, Castaing D, Ericzon BG, Otte JB, Rolles K. Hepatic transplantation in Europe. Lancet 2: 674–676, 1987
Coyle D, Tolley K. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate? PharmacoEconomics 2: 153–162, 1992
DRG i Sverige (DRG in Sweden) — Anpassning och registerstudier. Spri rapport nr 28. Spri, Stockholm, 1990
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford, New York, Toronto, 1990
FASS 1991. Farmaceutiska specialiteter i Sverige (Pharmaceutical Specialties in Sweden). LINFO, (Lakemedelsinformation AB), Stockholm, 1991
Hjalte K, Lindgren B, Persson U. The cost effectiveness of cholesterolreducing drugs in the primary prevention of coronary heart disease in Sweden. IHE Working Paper, 1991: 5, Swedish Institute for Health Economics, Lund, 1991
Jawets E. Antifungal Agents. In Katzung B-G (Ed.) Basic and clinical pharmacology, 2nd ed., pp. 559–563, Large Medical Publications, Los Altos, California, 1984
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53: 457–481, 1958
Kaplan RM, Bush JW. Health related quality of life measurement for evaluation research and policy analysis. Health Psychology 1: 61–80, 1982
Lindgren B, Persson U. The cost-effectiveness of a new antihypertensive drug, doxazosin. Current Therapeutic Research 45: 738–760, 1989
Lindholm A, Albrechtsen D, Tufveson G, Karlberg I, Persson NH, et al. A randomised trial of cyclosporine and prednisolone versus cyclosporine, azathioprine and prednisolone in primary cadaveric renal transplantation. Transplantation, submitted for publication, 1991
Lopez-Berestein G, Bodey GP, Frankel LS, Metha K. Treatment of hepatosplenic candidiasis with liposomal amphotericin B. Journal of Clinical Oncology 5: 310–317, 1987
Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. Journal of Antimicrobial Chemotherapy 28 (Suppl. B): 83–91, 1991
Organtransplantationer (Organ Transplantations) SBU, The Swedish Council on Technology Assessment in Health Care, Stockholm, 1989
Persson U. Cost of road traffic accidents in Sweden. Report from the Department of Traffic Planning, and Engineering, Lund Institute of Technology, University of Lund, Sweden, 1989
Regiontaxor 1991 for sodra sjukvardsregionen (Regional hospital fees for the Southern part of Sweden) Samverkansnamnden, Lund, 1991
Ringden O, Aschan J, Bostrom L, Dahllöf G, Tollemar J. Allogenic bone marrow transplantation at Huddinge Hospital and strategies to improve survival. In Terasaki P (Ed.) Clinical transplantations 1990, Los Angeles, 1990
Ringden O, Meunier F, Tollemar J, Ricci P, Tura F. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy 28 (Suppl. B): 73–82, 1991
Stason W. Opportunities for improving the cost-effectiveness of antihypertensive treatment. American Journal of Medicine 81 (Suppl. 6C): 45–49, 1986
Tollemar J, Ringden G, Tyden G. Liposomal amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clinical Transplantation 4: 167–175, 1990
Tyden G, Tibell A, Bolinder J, Ostman J, Groth CG. Pancreatic transplantation using enteric exocrine diversion: the Stockholm experience with 117 Cases. In Terasaki P (Ed.) Clinical transplantations 1990, Los Angeles, 1990
Weinstein M, Stason W. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annual Review of Public Health 6: 41–63, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Persson, U., Tennvall, G.R., Andersson, S. et al. Cost-Effectiveness Analysis of Treatment with Liposomal Amphotericin B versus Conventional Amphotericin B in Organ or Bone Marrow Transplant Recipients with Systemic Mycoses. PharmacoEconomics 2, 500–508 (1992). https://doi.org/10.2165/00019053-199202060-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199202060-00008